ACAlessandro Cordiale

Alessandro Cordiale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandro Cordiale has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An innervated and vascularized HNSCC-on-a-chip model built on defined and tunable engineered extracellular matrices

    by Alessia Maria Pignataro, Cornelia Christina Schwarz, Emilia Wiechec, Alessandro Cordiale, Shyama Sasikumar, Alexander Jenssen, Taka Ariyaberg, Lalit Pramod Khare, Ehsanul Hoque Apu, Karin Roberg, et al.

    Understanding the tumor microenvironment requires experimental platforms that faithfully recapitulate its key components. Here, we present an innervated and vascularized head and neck squamous cell carcinoma (HNSCC)-on-a-chip platform built with fully defined and tunable engineered extracellular matrices (eECMs). In a stepwise increase of complexity, we first cocultured patient-derived HNSCC cells, cancer-associated fibroblasts, and endothelial cells within tailored eECMs, revealing extracellular matrix-dependent differences in transcriptional state, multicellular self-organization, and chemotherapeutic sensitivity. We then integrated these three-dimensional constructs into a cancer–vasculature interface, which enabled analysis of eECM-dependent directional collective migration and invasion. Finally, we incorporated trigeminal innervation through injectable 3D human bioengineered trigeminal ganglia, establishing a chip-based innervation–tumor–vasculature tri-interface. Together, this all-human platform integrates fully defined ECM, vasculature, and innervation in a single modular system to investigate tumor organization, invasion, and therapeutic responses within a controlled human microenvironment.


  • Open Access

    IntravChip: a vascularized and perfused microfluidic model of the primary tumor microenvironment to collect intravasated tumor cells

    by Marie Floryan, Alessandro Cordiale, Heather Jensen, Julie Chen, Zixian Guo, Vinayak Vinayak, Sina Kheiri, Ritu Raman, Vivek B Shenoy, Elena Cambria, et al.

    Hematogenous metastasis is initiated when tumor cells (TCs) intravasate into the vasculature, yet intravasation remains poorly understood because it is difficult to observe in vivo and intravasated TCs are challenging to isolate. To address these challenges, we developed IntravChip, a continuously perfused microfluidic platform containing a vascularized primary tumor microenvironment (TME) enabling the observation of TC intravasation, and a downstream chamber to collect intravasated TCs. The IntravChip can support a high TC concentration in the TME while maintaining complete vascular perfusion, which we found was necessary to collect intravasated cells. Using MDA-MB-231 breast TCs, we identified an optimal initial TC seeding density that, by day 9, yields a densely populated TME and 100-440 collected intravasated TCs. We validated the IntravChip across several TC types, showing that MDA-MB-231 and MV3 TCs have the highest intravasation rates while MCF-7 TCs have low intravasation efficiency. We also show that the IntravChip is compatible with super-resolution nano-imaging. Our devices enabled high-quality STORM imaging, which revealed that H3K9me3 nanodomains are significantly differentially distributed in intravasated MDA-MB-231 tumor cells compared to those residing in the TME. Finally, the IntravChip was validated as a platform to test the effects of anti-cancer drugs on tumor cells and on the vasculature. We showed that a 5 μM concentration of sorafenib reduced intravasation events by 69% without impacting the morphology of the microvascular networks (MVNs), while a 10 μM concentration led to a significant decrease in vessel diameter. This platform enables quantitative analysis of TC intravasation, collection of intravasated TCs for characterization, and screening of anti-metastatic therapies.